AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03675932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
Description: Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
Study NCT01147484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: foretinib, at a continuous oral daily dose of 60 mg
Study NCT03072836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analysing microbiota
Description: 16SRNA gene sequencing of feces
Study NCT01154569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg single dose
Study NCT03361423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerivio Migra-1 active device
Description: The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site.
Study NCT03361423 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nerivio Migra-1 Sham device
Description: The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
Study NCT01568489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-009 Liposomal Gel
Description: a semi-transparent red-color gel and is supplied as a laminated tube
Study NCT01620905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Single level cervical spine joint manipulation
Study NCT01858467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Portex endotracheal tube 6.5mm or 7.0mm internal diameter
Study NCT01568489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HL-009 Liposomal Gel
Description: a semi-transparent red-color gel and is supplied as a laminated tube
Study NCT03028272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skye Barrier
Description: Substrate derived from amniotic tissue that is FDA-approved for human implantation
Study NCT03028272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascia
Description: Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
Study NCT03252795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterus transplantation
Description: transplantation of a uterus from a deceased donor
Study NCT03617484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
Study NCT03617484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
Study NCT00297271 — intervention group
Intervention type: OTHER
Intervention: Current treatment practice of each participating physician
Description: Patients will be observed for the evaluation of current management strategies.
Study NCT01765985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSORIAMED
Description: V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs.
Study NCT00741676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy-assisted distal gastrectomy
Description: 10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3\~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
Study NCT01765985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLACEBO
Description: V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs.
Study NCT01841320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated methadone and antiretroviral therapy (iMART) clinic
Study NCT03876574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSA-guided implantation of hepatic artery infusion pump
Description: Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
Study NCT00741676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open distal gastrectomy
Description: Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
Study NCT01376986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical, psychological and social activation
Study NCT02611271 — intervention group
Intervention type: OTHER
Intervention: Monitoring of antibiotic drug removal
Description: No study specific intervention will be performed
Study NCT03124589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Gambling Internet Intervention
Description: CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
Study NCT00981214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
Study NCT01858467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway
Description: Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
Study NCT04131569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ESBL-E fecal carriage screening according to routine care
Description: ESBL-E fecal carriage screening according to routine care
Study NCT01921816 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prismocitrate 18/0, Prism0cal
Description: Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
Study NCT02272725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen
Study NCT02272725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tasteless and inert visually identical (to ibuprofen) pills
Study NCT06764550 — intervention group
Intervention type: OTHER
Intervention: This is an observational study, participants are not assigned an intervention as part of the study.
Description: This is an observational study, participants are not assigned an intervention as part of the study.
Study NCT00810836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BG00012
Description: oral
Study NCT00810836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BG00012
Description: Oral
Study NCT00810836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo
Study NCT02031367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Corticosteroid arm
Study NCT02031367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma
Study NCT00656279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dietary phosphorus education
Description: Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
Study NCT00514683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose BIBF1120 once daily
Description: low dose BIBF1120 once daily
Study NCT00514683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose BIBF 1120 twice daily
Description: low dose BIBF 1120 twice daily
Study NCT00514683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermediate dose BIBF 1120 twice daily
Description: intermediate dose BIBF 1120 twice daily
Study NCT00514683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose BIBF 1120 twice daily
Description: high dose BIBF 1120 twice daily
Study NCT00514683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01974115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
Study NCT00806234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole or Perphenazine
Description: Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
Study NCT00806234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
Study NCT00806234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Description: Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
Study NCT00006364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Description: Given IV or SC
Study NCT00006364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00006364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01331460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBT
Description: Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors.
Study NCT01331460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case-Management
Description: Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs
Study NCT02417103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 (Liraglutide)
Description: GLP-1 Analogon
Study NCT02417103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03610763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.
Study NCT03610763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Constraint Induced Movement Therapy
Description: In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
Study NCT00209807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 10 mg/d for 6 weeks
Study NCT00209807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reboxetine
Description: Reboxetine 8 mg/d for 6 weeks
Study NCT00209807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: This group of healthy volonteers will receive no drug and will be a healthy comparator.
Study NCT03178279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Health Plan
Description: Use of a Physical Health Plan by service users
Study NCT01313143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOP200704
Description: Comparison of AOP200704 with Esmolol
Study NCT01313143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol hydrochloride, infusion
Description: Comparison of AOP200704 with Esmolol
Study NCT00089089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00089089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00089089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01343602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mod. Constraint-Induced Movement Therapy
Description: Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training.
Study NCT01343602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapy as usual
Description: Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
Study NCT04436263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplement
Description: A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
Study NCT04436263 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
Study NCT04585659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
Study NCT04080752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 will be administrated orally.
Study NCT04080752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study NCT03219385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirabilis System
Description: The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
Study NCT01906684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
Study NCT02026180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropuncture Access
Description: Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
Study NCT03486028 — intervention group
Intervention type: OTHER
Intervention: Adherence to ASAM protocols
Description: ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.
Study NCT03486028 — intervention group
Intervention type: OTHER
Intervention: Non-adherence to ASAM protocols
Description: These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
Study NCT02607982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
Study NCT02607982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.